Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > COLUMN
COLUMN
-
Social Networking in Japan’s Pharmaceutical Industry
May 1, 2012
-
The Eight Characteristics of a Great Leader
April 2, 2012
-
Maurer’s Healthcare Insight (143)
March 26, 2012
-
Maurer’s Healthcare Insight (142)
February 27, 2012
-
Maurer’s Healthcare Insight (141)
January 30, 2012
-
Maurer’s Healthcare Insight (140)
December 26, 2011
-
Maurer’s Healthcare Insight (139)
December 12, 2011
-
Maurer’s Healthcare Insight (138)
November 21, 2011
-
Maurer’s Healthcare Insight（137）
October 17, 2011
-
Maurer’s Healthcare Insight (136)
September 12, 2011
-
Maurer's Healthcare Insight (135)
August 15, 2011
-
Maurer's Healthcare Insight (134)
August 1, 2011
-
Maurer's Healthcare Insight (133)
July 11, 2011
-
Maurer's Healthcare Insight (132)
May 30, 2011
-
Maurer's Healthcare Insight (131)
April 18, 2011
-
Maurer's Healthcare Insight (130)
January 24, 2011
-
Maurer's Healthcare Insight (129)
January 3, 2011
-
Maurer's Healthcare Insight (128)
December 13, 2010
-
Maurer's Healthcare Insight (127)
November 29, 2010
-
Maurer's Healthcare Insight (126)
November 8, 2010
ページ
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…